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Abstract
Background: Nerve growth factor (NGF) is the prototypical target-derived neurotrophic factor required for
sympathetic neuron survival and for the growth and ramification of sympathetic axons within most but not all
sympathetic targets. This implies the operation of additional target-derived factors for regulating terminal
sympathetic axon growth and branching.
Results: Here report that growth differentiation factor 5 (GDF5), a widely expressed member of the transforming
growth factor beta (TGFβ) superfamily required for limb development, promoted axon growth from mouse superior
cervical ganglion (SCG) neurons independently of NGF and enhanced axon growth in combination with NGF. GDF5
had no effect on neuronal survival and influenced axon growth during a narrow window of postnatal development
when sympathetic axons are ramifying extensively in their targets in vivo. SCG neurons expressed all receptors capable
of participating in GDF5 signaling at this stage of development. Using compartment cultures, we demonstrated that
GDF5 exerted its growth promoting effect by acting directly on axons and by initiating retrograde canonical Smad
signalling to the nucleus. GDF5 is synthesized in sympathetic targets, and examination of several anatomically
circumscribed tissues in Gdf5 null mice revealed regional deficits in sympathetic innervation. There was a marked,
highly significant reduction in the sympathetic innervation density of the iris, a smaller though significant reduction in
the trachea, but no reduction in the submandibular salivary gland. There was no reduction in the number of neurons
in the SCG.
Conclusions: These findings show that GDF5 is a novel target-derived factor that promotes sympathetic axon growth
and branching and makes a distinctive regional contribution to the establishment of sympathetic innervation, but
unlike NGF, plays no role in regulating sympathetic neuron survival.
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Background
Nerve growth factor (NGF) is the prototypical target-
derived neurotrophic factor on which the foundations of
neurotrophic theory are based [1]. In the developing per-
ipheral nervous system, postganglionic sympathetic neu-
rons and the majority of sensory neurons depend for
their survival on a supply of NGF synthesized in their
targets [2, 3]. While target-derived NGF plays no role in
guiding axons to their targets during development [4], it
acts locally on axon terminals within the target field to
promote growth and branching within most but not all
targets of NGF dependent neurons [5, 6]. This implies
the operation of additional target-derived factors that
regulate the terminal growth and branching of axons of
NGF-dependent neurons in certain target tiisues.
Here we report that growth differentiation factor-5
(GDF5), a widely expressed member of the bone mor-
phogenetic protein/growth differentiation factor (BMP/
GDF) family which constitutes a collection of closely
related proteins within the TGFβ superfamily [7], is a
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novel regulator of sympathetic axon growth, acting dur-
ing the stage in development when the axon terminals
of NGF-dependent sympathetic neurons of the superior
cervical ganglion (SCG) neurons are growing and
branching extensively in their targets in vivo. GDF5 has
extensively characterized roles in chondrogenesis, joint
formation, skeletal, tendon and ligament morphogenesis
[8–10]. Several reports have also implicated GDF5 in
neuronal development. GDF5 enhances the survival of
embryonic midbrain dopaminergic neurons and pro-
motes neurite outgrowth from these neurons in vitro
[11, 12], it promotes the growth and elaboration of pyr-
amidal cell dendrites in the embryonic hippocampus
both in vitro and in vivo [13] and has a minor survival-
promoting action on embryonic chicken dorsal root gan-
glion (DRG) neurons in vitro [14]. Here we report and
characterize novel, physiologically relevant functions for
GDF5 in sympathetic neuron development. We show
that GDF5 promotes the growth and branching of sym-
pathetic axons during a narrow window of postnatal
development and functions as a novel target-derived
regulator of sympathetic innervation in vivo that makes
a distinctive regional contribution to the establishment
of sympathetic innervation.
Results
GDF5 enhances neurite growth and branching from
neonatal SCG neurons
GDF5 increased the size of the neurite arbors of new-
born mouse (P0) SCG neurons cultured at low density
in defined medium. It enhanced neurite arbor size of
neurons cultured with saturating concentrations of NGF
and promoted neurite growth from neurons cultured
without NGF in medium containing the broad-spectrum
caspase inhibitor Boc_D_FMK to prevent apoptosis of
the neurons in the absence of NGF (Fig. 1a). Analysis of
the neurite arbors of large numbers of neurons showed
that GDF5 promoted highly significant increases in over-
all neurite length and the number of branch points in
both the presence and absence of NGF (Fig. 1b). Dose
response analysis revealed that the neurite growth-
promoting effect of GDF5 reached saturation at 10 ng/ml
(Fig. 1c).
Analysis of the influence of GDF5 on SCG neurons in
cultures established over a range of ages revealed that
the neurite growth enhancing effect of GDF5 was
restricted to a narrow developmental window in the im-
mediate postnatal period. Sholl analysis, which provides
a graphic illustration of neurite length and branching
with distance from the cell body, showed that the effect
of GDF5 on neurite growth and branching was evident
at P0 and P1 but not before or after this period (Fig. 1d).
This contrasts with the neurite growth promoting effect
of NGF, which is evident from the time the earliest
sympathetic axons reach their targets to well after the
phase of programmed cell death [15–17]. In marked
contrast to NGF, which promotes the survival of SCG
neurons in addition to promoting neurite growth, GDF5
did not promote the survival of SCG neurons on its own
and did not increase the number of neurons surviving
with NGF (Fig. 1e). These results show that GDF5
enhances neurite growth from sympathetic neurons in-
dependently of NGF without affecting neuronal survival.
Because the neurites in short_term SCG cultures are
exclusively axons [18], confirmed by absence of dendrite
markers in SCG neurons cultured with or without GDF5
for 24 h (not shown), our findings suggest that GDF5
promotes axon growth and branching from SCG neu-
rons independently of NGF without affecting neuronal
survival over a narrow developmental window during
the period when sympathetic axon terminals are growing
and branching within their targets.
GDF5 acts locally on axon terminals to promote axon
growth
To determine if, like NGF, GDF5 is capable of acting lo-
cally on axons to promote their growth, we cultured these
neurons in microfluidic devices in which the cell bodies
and axon terminals are grown in separate compartments
(Fig. 2a). P0 SCG neurons were seeded into one compart-
ment of a two-compartment device that contained NGF
in both compartments. After 24 h incubation, maximal
axon length in the axon compartment was quantified.
Whereas supplementation of the axon compartment by
GDF5 caused a highly significant increase in axon length
compared to NGF alone, supplementation of the soma
compartment by GDF5 did not enhance axon length com-
pared to NGF alone (Fig. 2b-e). It was also clearly evident
that addition of GDF5 to the axon compartment, but not
the soma compartment, increased neurite density in the
axon compartment (Fig. 2b-d). These data show that
GDF5 acting locally on sympathetic axons, but not on
neuronal soma, significantly increases axon growth
Expression of GDF5 receptors on developing SCG neurons
Members of the BMP/GDF family mediate their actions
via a heterodimeric complex of type I and type II serine-
threonine kinase receptors [19]. Among type I receptors,
GDF5 binds most efficiently to BMPR1B expressed alone
on cell lines but binds weakly to BMPR1A when co-
expressed with ACVR2A (ActRII). Receptor reconstitu-
tion experiments in Mv1Lu epithelial cells have shown
that GDF5 is able to transduce a signal via BMPR1B in
combination with either ACVR2A or BMPR2 (BMPRII),
but is also able to signal somewhat less effectively via
BMPR1A in combination with ACVR2A [20].
Transcripts encoding BMPR1B, BMPR2, BMPR1A and
ACVR2A were expressed in the developing SCG from
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E14 to at least P10, which spans the period over which
SCG axons first reach their target tissues and sympa-
thetic innervation is established. The expression profiles
for Bmpr1a mRNA and Acvr2a mRNA (Fig. 3a) and
Bmpr1b mRNA and Bmpr2 mRNA (Fig. 3b) showed an
overall small decrease from E14 to P10.
Immunocytochemistry revealed that antibodies to each
receptor stained the neurites of virtually all P0 SCG neu-
rons in culture (Fig. 3c to f). Cultures incubated with
secondary antibody alone exhibited no background im-
munofluorescence (not shown). These studies suggest
that receptor complexes containing BMPR1B and/or
BMPR1A are available for mediating the neurite growth-
promoting effects of GDF5.
GDF5 promotes retrograde canonical Smad signalling
along SCG axons
In common with other members of the BMP/GDF fam-
ily, GDF5 activates canonical Smad 1/5/8 signaling [21],
which is required for GDF5 responsiveness in neurons
[13]. To ascertain whether GDF5 could initiate retro-
grade Smad signaling to the nucleus, we first confirmed
that GDF5 is able to activate Smads 1/5/8 in SCG neu-
rons. Western blot analysis showed that GDF5 increased
Smad 1/5/8 phosphorylation in P0 SCG neurons as early
as 5 minutes after GDF5 treatment (Fig. 4a). Immunocyto-
chemistry using an antibody that recognizes phospho-
Smad1/5/8 revealed that GDF5 promoted rapid nuclear
accumulation of phospho-Smad1/5/8 in dissociated cul-
tures of SCG neurons (Fig. 4b and c).
To assess retrograde Smad signaling, P0 SCG neurons
were incubated for 12 h in compartment cultures con-
taining NGF in both compartments before GDF5 was
added to the axon compartment. After an hour, calcein-
AM was added to the axon compartment to identify
neurons with axons projecting into this compartment.
The cultures were then fixed and stained for nuclear
phospho-Smad-1/5/8. GDF5 treatment of sympathetic
axons resulted in a highly significant increase in nuclear
phospho-Smad1/5 immunoreactivity in neurons that
projected axons into the axon compartment, but not in
those neurons whose axons did not cross into this com-
partment (Fig. 4d and e). This demonstrates that GDF5
acting on sympathetic axons induced retrograde canon-
ical Smad signaling along these axons, leading to nuclear
accumulation of phospho-Smad proteins.
To test directly the importance of GDF5 receptor-
dependent Smad activation and Smad-dependent gene
Fig. 1 GDF5 promotes neurite growth from cultured neonatal SCG neurons. a Photomicrographs of representative P0 SCG neurons cultured for
24 h with or without 10 ng/ml GDF5 and/or 10 ng/ml NGF. b Branch point number and total length of neurite arbors of P0 SCG neurons cultured for
24 h with or without 10 ng/ml GDF5 and/or 10 ng/ml NGF. c Neurite arbor lengths of P0 SCG neurons cultured for 24 h with different concentrations
of GDF5. d Sholl analysis of the arbors of E18, P0, P1 and P2 SCG neurons cultured for 24 h with and without 10 ng/ml GDF5. Cultures without NGF
received 50 μM Boc_D_FMK to prevent apoptosis. Mean ± SEM of data from at least 150 neurons in each condition from 3 independent experiments
are shown (** P < 0.01 and *** P < 0.001, statistical comparison with control, one-way ANOVA with Fisher’s post hoc). e Percentage survival of P0 SCG
neurons cultured for 24 h in the absence of Boc_D_FMK with or without 10 ng/ml GDF5 in the absence or presence of 10 ng/ml NGF (mean ± SEM of
the results of 3 independent experiments; n.s. = not significant)
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transcription on neurite growth, we co-transfected P0
SCG neurons with a reporter construct in which GFP is
under the control of Smad binding elements together
with either a pcDNA plasmid that expresses a constitu-
tively active BMPR-IB (caBMPR-IB) [22] or an empty
pcDNA control plasmid. Quantification of the reporter
signal 24 h after transfection revealed that the
caBMPR-IB promoted a highly significant increase in
Smad-dependent gene transcription that was com-
pletely prevented by a co-transfected decoy double-
stranded DNA-oligonucleotide that contains the Smad
consensus binding sequence but not by a control oligo-
nucleotide with a scrambled sequence (Fig. 5a). The
caBMPR-IB also promoted highly significant increases
in neurite length (Fig. 5b), branch point number
(Fig. 5c) and overall neurite arbor size and complexity
(Fig. 5d and e) that were completely prevented by the
Smad oligonucleotide decoy but not by the control
oligonucleotide. There were no significant differences
in the length and branching of the neurite arbors of
neurons transfected with the control plasmid plus ei-
ther decoy DNA or scrambled DNA (Fig. 5b-c).
GDF5 plays a distinctive role in establishing sympathetic
innervation in vivo
To ascertain whether the increase in sympathetic axon
growth and branching brought about by GDF5 in vitro
contributes to the establishment of sympathetic innerv-
ation in vivo, we used tyrosine hydroxylase immuno-
fluorescence to identify sympathetic fibers and quantify
sympathetic innervation density in wild type mice and
mice that are either heterozygous or homozygous for the
Gdf5bp null mutation, a frame-shift mutation in the Gdf5
gene [23]. For this analysis, we studied the submandibu-
lar salivary gland, trachea and iris. While the terminal
growth and branching of sympathetic axons in the sub-
mandibular salivary gland is dependent on NGF, the ter-
minal ramification of sympathetic axons in the trachea
occurs independently of NGF [5]. Our analysis was car-
ried out at P10, which is after the period of development
when GDF5 enhances neurite growth in vitro and is at a
Fig. 2 GDF5 acts locally on axon terminals to promote axon growth. a
Schematic illustration of the two-chamber microfluidic device. The inset
shows a neuron with its cell body in the soma compartment on the left
extending its axon arbor through a microchannel into the axon
compartment on the right. b-d Photomicrographs of representative P0
SCG neurons cultured in defined medium for 24 h with 10 ng/ml NGF
in both compartments (b), NGF in both compartments plus
10 ng/ml GDF5 in the axonal compartment (c) and NGF in both
compartments plus 10 ng/ml GDF5 in the soma compartment (d).
Scale bar = 200 μm. e Bar chart of axon length measurements in
the axon compartment (*** P < 0.0001, statistical comparison with
NGF alone, ANOVA)
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stage in vivo when the sympathetic innervation of these
tissues has become well established.
Quantification of tyrosine hydroxylase immunofluores-
cence in tissue sections revealed marked, highly significant
reductions in the iris of heterozygous and homozygous
mice compared with wild type mice (Fig. 6a). The level of
tyrosine hydroxylase immunoreactivity in the irides of het-
erozygous mice was intermediate between that of wild type
and homozygous mice, indicative of a gene dosage effect.
There was no significant reduction in the level of tyrosine
hydroxylase immunoreactivity in the submandibular saliv-
ary gland of Gdf5bp mice compared with wild type mice
(Fig. 6b). Because there are fewer sympathetic fibers in the
trachea, we assessed innervation density by quantifying the
density of tyrosine-hydroxylase-positive fibers in cleared
whole-mount tissue preparations. This analysis revealed a
statistically significant reduction in tyrosine hydroxylase-
positive nerve fiber density in Gdf5bp mice compared with
wild type mice (Fig. 6c). Figure 6d illustrates representative
tyrosine hydroxylase-immunolabeled sections through the
irides of wild type mice and Gdf5bp mice, illustrating the
clear decrease in sympathetic innervation density in the
latter. To determine the site of GDF5 expression and to as-
certain its relation to sympathetic fibers in the iris, we
double labeled sections of the iris for tyrosine hydroxylase
and GDF5. This showed prominent GDF5 immunoreactiv-
ity throughout the stroma and tyrosine hydroxylase-
positive fibers ramifying within the stroma (Fig. 6e). GDF5
immunoreactivity was not observed in the irides of Gdf5bp
mice, demonstrating the specificity of the anti-GDF5 anti-
body used (Fig. 6e). These observations show that GDF5 is
expressed by cells in the target field. Figure 6f illustrates
representative tyrosine hydroxylase-immunolabeled whole
mounts of the trachea of wild type mice and Gdf5bp mice.
Neuron counts in the SCG at P5 and P10 revealed no
significant differences between wild type mice and
Gdf5bp mice at each age (Fig. 6g), suggesting that SCG
neurons are not dependent on GDF5 for survival when
sympathetic innervation is being established during the
postnatal period. Taken together, these findings suggest
Fig. 3 Expression of GDF5 receptors. a, b Expression of transcripts encoding GDF5 receptors in the SCG at stages from E14 to P10 relative to the
geometric mean of Gapdh, Sdha and Hprt1 reference mRNAs (mean ± SEM, n = 3 per age). a Relative levels of Bmpr1a and Acvr2a mRNAs normalised
to the peak of expression at E14 and P0, respectively. b Relative levels of Bmpr1b and Bmpr2 mRNAs normalised to the peak of expression at E16. c to
f Photomicrographs of representative P0 SCG neurons cultured for 24 h with NGF and double labelled for β-III tubulin and either BMPR1A (c), ACVR2A
(d), BMPR2 (e) or BMPR1B (f). Scale bar = 40 μm
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that GDF5 plays a tissue-selective role in establishing
sympathetic innervation in vivo without affecting SCG
neuron number.
Discussion
We have discovered and characterized novel and dis-
tinctive functions for GDF5 in the developing peripheral
nervous system and show that these differ in several re-
spects from the potential roles of GDF5 reported for
other neurons. First, whereas GDF5 promotes the
growth and branching of axons from sympathetic neu-
rons, GDF5 promotes the growth and elaboration of
dendrites but not axons from hippocampal pyramidal
cells [13]. Second, whereas GDF5 neither promotes the
survival of sympathetic neurons alone nor enhances the
survival of these neurons in combination with NGF,
GDF5 has a minor survival-promoting action on DRG
neurons alone and enhances the survival-promoting ac-
tion of NGF and NT3 in vitro [14]. GDF5 also promotes
the survival of midbrain dopaminergic neurons in vitro
[12] and is neuroprotective for these neurons exposed to
toxic insults both in vitro [11, 24] and in vivo [25].
Third, whereas the effects of GDF5 on sympathetic neu-
rons are restricted to a very narrow postnatal window of
Fig. 4 GDF5 promotes retrograde canonical Smad signalling along SCG axons. a Representative Western blot for phospho-Smad1/5/8 in P0 SCG
neurons treated with GDF5 for 5, 10, and 15 min or untreated (0′) 12 h after plating using βIII tubulin and total ERK1/2 as loading standards. The
bar chart plots the relative levels of phospho-Smad1/5/8 from densitometry of multiple blots at the 0 and 15 min time points (mean ± SEM). b
Representative P0 SCG neurons immunolabeled for phospho-Smad-1/5/8 and β-III tubulin after either 30 min treatment with GDF5 or untreated
(Control) 12 h after plating. c Percentage increase in nuclear phospho-Smad-1/5/8 immunolabeling in P0 SCG neurons treated with GDF5 for the
indicated times relative to untreated control levels. d Representative P0 SCG neurons immunolabeled for phospho-Smad-1/5/8 after 60 min treatment
of their axons with 10 ng/ml GDF5 in compartment cultures 12 h after plating. Addition of calcein-AM to the axon compartment was used to identify
neurons that had projected axons into the axon compartment (white arrows), whereas unlabelled cells (yellow arrows) had not projected
axons into the axon compartment. DAPI labelling indicates all cell nuclei in the field and the phase contrast image shows the location of
the compartment barrier with two of its microchannels. Neurons whose axons had been exposed to GDF5 had a clear increase in nuclear
accumulation of phospho-Smad proteins. Scale bar = 30 μm. e Relative intensity of nuclear phospho-Smad immunofluorescence in neurons
with axons that had or had not projected into the axon compartment (mean ± SEM, *P < 0.05, ** P < 0.01, *** P < 0.001, statistical comparison
with control, one-way ANOVA with Fisher’s post hoc)
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development, midbrain dopaminergic neurons remain
responsive to GDF5 from embryonic stages into the
adult [11, 12, 25]. Our current study together with previ-
ous work documents the multiple distinctive actions of
GDF5 in the developing and mature nervous system.
In addition to GDF5, several other factors have been
shown to enhance sympathetic axon growth and branch-
ing over restricted windows of development during the
stage when sympathetic axons are ramifying extensively
in their targets, without affecting neuronal survival.
GDF5 and these other factors do not have redundant
functions, but act by different mechanisms and have dis-
tinctive roles in establishing sympathetic innervation
in vivo.
Both TNFR1 [26], acting via a TNF reverse signaling
mechanism, and GDF5 act in a target-derived manner.
TNFR1 and GDF5 are expressed in target tissues and act
on sympathetic axon terminals to promote growth and
branching. However, whereas studies of Gdf5bp mice re-
veal a distinctive regional requirement for GDF5 in vivo
in the establishment of sympathetic innervation,
multiple tissues display defective sympathetic innerv-
ation in both Tnfr1−/− and Tnf−/− mice [25]. It is not
clear why GDF5 plays a major role in establishing sym-
pathetic innervation in the iris and to a lesser extent in
the trachea, but not in the submandibular gland. Like
TNFR1, GDF5 is widely expressed in multiple tissues,
and the level of GDF5 is no higher in the iris than in the
submandibular gland (data not shown). For this reason,
the marked innervation defect in iris of Gdf5bp mice
cannot be explained simply by regional differences in
GDF5 expression and access of sympathetic axons to
GDF5. Whether a subset of SCG neurons that innervate
the iris and trachea respond to GDF5 in vivo, either be-
cause they are pre-specified to respond or because
target-derived factors regulate GDF5 responsiveness, is
an intriguing issue for future work. The trachea is the
one tissue of the many analyzed whose sympathetic in-
nervation is completely independent of NGF [5]. The
small, though significant, decrease in the sympathetic in-
nervation of the trachea of Gdf5bp mice shows that
GDF5 makes a significant contribution to establishing
Fig. 5 Canonical Smad signalling promotes neurite growth in SCG neurons. a Smad-dependent transcriptional activity in P0 SCG neurons 24 h
after transfection with the Smad-GFP reporter plus either the caBMPR-IB plasmid or pcDNA3.1 control plasmid and either Smad decoy oligonucleotides
or scrambled control decoy oligonucleotides. b Length, c branch number and d Sholl analysis of the neurite arbors of P0 SCG neurons 24 h
after transfection with the indicated plasmids and oligonucleotides. For clarity, the Sholl plot includes only one control plasmid condition. e
Photomicrographs of representative P0 SCG neurons 24 h after transfection with the plasmids indicated. Mean ± SEM of data from at least 150
neurons in each condition from 3 independent experiments are shown (*** P < 0.001, statistical comparison with control, one-way ANOVA
with Fisher’s post hoc)
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Fig. 6 Selective sympathetic innervation deficits in mice possessing the Gdf5bp mutation. a-c Relative innervation density assessed by quantification of
tyrosine hydroxylase-positive sympathetic fibres at P10 in the irides (a), submandibular glands (b) and trachea (c) of wild type mice (WT) and mice that
are heterozygous (Het) or homozygous (Gdf5bp) for the Gdf5bp null mutation. The level of tyrosine hydroxylase staining is normalised to 100
for the tissue of wild type mice (mean ± SEM, *P < 0.01, **P < 0.00001, ***P < 0.0000001, statistical comparison with wild type, one-way ANOVA
with Tukey HSD post hoc, n = 10 animals per genotype for the iris, n = 5 animal per genotype for the submandibular gland and the trachea).
d Representative sections of the irides of P10 wild type and Gdf5bp mice stained for tyrosine hydroxylase. The boundaries of the iris are
indicated by the dashed lines. e Representative sections of the iris of a P10 wild type and Gdf5bp mice double stained for GDF5 and tyrosine
hydroxylase. Scale bar = 100 μm. f Representative whole mounts P10 wild type and Gdf5bp mice stained for tyrosine hydroxylase. Scale bar = 100 μm.
g Numbers of neurons in the SCG of P5 and P10 wild type and Gdf5bp mice (n = 3 per genotype)
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tracheal sympathetic innervation. The other factor or
factors required for promoting the ramification of sym-
pathetic fibres in this tissue remain elusive.
Like GDF5, GITR signaling and CD40 signaling en-
hance sympathetic axon growth during the immediate
postnatal period without affecting neuronal survival and
play roles in establishing sympathetic innervation in vivo
[27, 28]. However, in contrast to the target-derived mode
of action of GDF5, GITR signaling and CD40 signaling
act by an autocrine mechanism. Also, in contrast to
GDF5, which promotes sympathetic axon growth alone
in the absence of NGF, stimulating these autocrine sig-
naling loops in the absence of NGF does not promote
sympathetic axon growth. Rather, these autocrine signal-
ing loops enhance the axon growth-promoting actions
of NGF [27, 28]. Despite modulating NGF responsive-
ness, Cd40−/− mice, like Gdf5bp mice, display regional
deficits in sympathetic innervation density [28]. This is
because NGF negatively regulates the expression of both
CD40 and its autocrine signaling partner CD40L, with
the result that these proteins are only expressed at func-
tionally relevant levels in low NGF-expressing tissues,
which are those that are selectively hypo-innervated in
Cd40−/− mice [28].
HGF [29] and Wnt5a [30] are another two factors that
enhance sympathetic axon growth by an autocrine
mechanism during the stage of development when sym-
pathetic axons are ramifying in their final targets. While
this activity has only been reported for HGF in vitro, the
importance of Wnt5a has been demonstrated in vivo in
mice in which Wnt5a is conditionally inactivated in
sympathetic neurons. In these mice, sympathetic fibres
reach their final targets, but display greatly reduced
growth and terminal arborization in multiple tissues,
which contrasts with the regional deficit observed in
Gdf5bp mice.
Most SCG neurons are generated between E11.5 and
birth [31, 32], the earliest sympathetic fibres reach SCG
targets at E13 [33] and the density of sympathetic in-
nervation of many tissues clearly increases between the
late fetal and early postnatal period [5]. Thus, the brief
window over which GDF5 enhances axon growth from
SCG neurons appears to occur shortly after sympathetic
axons have arrived at their target tissues and are ramify-
ing within and refining connections in these tissues.
GDF5 binds efficiently to BMPR1B and transduces a sig-
nal via BMPR1B in combination with either BMPR2 or
ACVR2A. However, GDF5 also binds BMPR1A weakly
when co-expressed with ACVR2A and transduces a sig-
nal in cell lines co-expressing BMPR1A and ACVR2A
[20]. We show that SCG neurons express BMPR1A and
ACVR2A as well as BMPR1B and BMPR2 during this
brief window of GDF5 responsiveness. However, we find
that transcripts for all receptors are expressed at similar
levels in the SCG for extended periods before and after
the window of GDF5 responsiveness. This suggests that
the timing of GDF5 responsiveness is unlikely to be due
to changes in receptor expression. This contrasts with
enhanced SCG axon growth brought about by activating
TNF reverse signaling and by activating the extracellular
Ca2+ sensitive receptor (CaSR). The developmental win-
dow of responsiveness of SCG neurons to TNFR1 and to
elevated extracellular Ca2+ coincides with peaks in TNF
[26] and CaSR expression [34]. Moreover, experimental
elevation of CaSR expression after the normal peak of
expression re-confers responsiveness to elevated extra-
cellular Ca2+ [34]. Our current findings raise the possi-
bility that the timing of GDF5 responsiveness might be
due to developmental changes in GDF5 local signaling,
retrograde GDF5 signaling or gene regulation.
GDF5 rapidly activates canonical Smad 1/5/8 signaling
in hippocampal pyramidal cells and rat midbrain dopa-
minergic neurons, and this in turn is required for GDF5-
promoted neurite growth and dendrite growth [13, 35].
Here we show that GDF5 also rapidly activates Smad 1/5/
8 signaling in sympathetic neurons, and demonstrate
using compartment cultures that treating sympathetic
axons with GDF5 results in the rapid appearance of
phospho-Smad immunoreactivity in the nucleus. This sug-
gests that GDF5 induces retrograde Smad signaling.
BMP4 also initiates retrograde Smad signaling along tri-
geminal sensory axons, and this plays a role in conveying
spatial patterning information from the periphery in the
developing trigeminal system [36]. Moreover, we show
that decoy DNA encoding the Smad consensus binding
sequence inhibits the enhanced axon growth associated
with GDF5 receptor-dependent Smad activation, suggest-
ing that Smad-dependent gene transcription enhances
axon growth in developing sympathetic neurons. While
these data suggest that retrograde Smad signaling to the
nucleus is important for GDF5-promoted axon growth,
compartment culture experiments show that GDF5 added
to the axon compartment enhances axon growth, whereas
GDF5 added to the soma compartment does not. This
observation raises the possibility that retrograde Smad sig-
naling alone is insufficient for GDF5-enhanced axon
growth, but that local signaling is also required. This has
parallels with other target-derived neurotrophic factors.
For example, whereas retrograde NGF/TrkA signaling to
the nucleus is required for NGF-promoted neuron sur-
vival, local TrkA-dependent signaling events in at the
growth cone are required for axon growth promoted by
NGF and NT3 [3, 37]. In future work it will be interesting
to dissect the local signaling events required for GDF5-
promoted axon growth.
Our current work demonstrates that GDF5 is one of a
growing number of factors that promote, by a diversity
of mechanisms, sympathetic axon growth and branching
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and have distinctive roles in establishing sympathetic in-
nervation in vivo without affecting neuronal survival. In
addition, factors expressed in target tissues such as
RANKL inhibit sympathetic axon growth and branching,
at least in vitro, without affecting neuronal survival [38].
In contrast, target-derived NGF performs the key dual
roles of sustaining sympathetic neuron survival and pro-
moting the growth and ramification of sympathetic
axons in target tissues in vivo. Indeed, there is overwhelm-
ing evidence that the limited availability of NGF in differ-
ent tissues governs the number of neurons that survive
the phase of naturally occurring death to innervate these
tissues [1]. Given this dual function, why are additional
factors that regulate axon growth but not survival
required? The most likely reason is that these additional
factors permit regional adjustments in innervation density
by the limited number of NGF-supported neurons that
innervate particular tissues.
Conclusions
We have discovered and characterized novel and dis-
tinctive functions for GDF5 in the developing nervous
system. GDF5 promotes the growth and branching of
sympathetic axons independently of NGF without affect-
ing sympathetic neuron survival during a brief window
of postnatal development when sympathetic axons are
ramifying within their targets. GDF5 is expressed in
sympathetic targets, acts directly on sympathetic axons
and initiates retrograde Smad signaling along these
axons to the nucleus. In vivo, there is a distinctive
regional requirement for GDF5 in the establishment of
sympathetic innervation, being required in the iris, not in
the submandibular gland and making a small, significant
contribution to the trachea, whose innervation is inde-
pendent of NGF. These findings extend our understanding
of the physiology of GDF5 and provide a deeper under-




C57BL6/J and brachypod (Gdf5bp) mice were obtained
from the Jackson Laboratory (Bar Harbor, Maine, USA).
While Gdf5bp mice are recognized by their short limb
phenotype, wild type and heterozygous mice are pheno-
typically indistinguishable and cannot be genotyped by
standard PCR-based methods. To generate litters con-
sisting of mice that are homozygous and heterozygous
for the Gdf5bp mutation, a female Gdf5bp mouse was
crossed with a male mouse that is heterozygous for the
Gdf5bp mutation. Heterozygous male mice were identi-
fied as phenotypically normal mice that produced litters
comprising phenotypically normal mice and Gdf5bp mice
when crossed with Gdf5bp females. Age-matched wild
type mice were obtained by crossing C57BL6/J mice. All
other studies were carried out on tissues obtained from
CD-1 mice.
Real-time PCR quantification of mRNA levels
SCG were harvested from embryonic and postnatal mice.
Because whole ganglia contain both neurons and satellite
cells, the RNA used for these studies is derived from both
cell types. Total RNA was isolated with the RNeasy Mini
extraction kit (Qiagen, Germany) and was reverse tran-
scribed with AffinityScript RT (Agilent). Reverse tran-
scription (RT) reactions were amplified using the Brilliant
III ultra-fast QPCR master mix (Agilent). QPCR assays for
Bmpr1a, BmprIb, Acvr2a, Bmpr2 and the reference genes,
Gapdh, Sdha and Hprt1 used dual-labeled probes to
detect PCR products. The forward and reverse primers
were as follows: Gapdh, 5′-gagaaacctgccaagtatg-3′ and 5′-
gggttgctgttgaagtc-3′; Sdha, 5′-ggaacactccaaaaacag-3′ and
5′-ccacagcatcaaattcat-3′; Hprt1, 5′-ttaagcagtacagccccaaaa
tg-3′ and 5′-aagtctggcctgtatccaacac-3′; Bmpr1a, 5′-tacgca
ggacaatagaat-3′ and 5′-aactatacagacagccat-3′; Bmpr1b, 5′-
agtgtaataaagacctcca-3′ and 5′-aactacagacagtcacag-3′; Bm
pr2, 5′-actagaggactggcttat-3′ and 5′-ccaaagtcactgataacac-
3′; Acvr2a, 5′-cgccgtctttcttatctc-3′ and 5′-tgtcgccgtttatctt
ta-3′. Dual labeled probes were: Gapdh, 5′- FAM-agacaa
cctggtcctcagtgt-BHQ1-3′; Sdha, 5′-FAM-cctgcggctttc
acttctct-BHQ1-3′; Hprt1, 5′-FAM-tcgagaggtccttttcaccagca
ag-BHQ1-3′; Bmpr1a, 5′- FAM-tgagcacaaccagccatcg-BH
Q1-3′; Bmpr1b, 5′-FAM-ccactctgcctcctctcaag-BHQ1-3′;
Bmpr2, 5′-FAM-cacagaattaccacgaggaga-BHQ1-3′; Acvr2a,
5′-FAM-tgctcttcaggtgctatacttggc-BHQ1-3′. The PCR was
performed (Mx3000P, Stratagene) for 40 cycles of 95 °C
for 10 sec, and 60 °C for 30 sec. Standard curves were gen-
erated for every PCR run with each primer/probe set
using serial five-fold dilutions of adult mouse brain RT
RNA (Zyagen). Bmpr1a, Bmpr1b, Bmpr2 and Acvr2a
mRNAs were expressed relative to the geometric mean of
the reference mRNAs.
Neuron cultures
Dissected SCG were trypsinized and the neurons were
plated at very low density (~200 neurons per dish) in
poly-ornithine/laminin-coated 35 mm tissue culture
dishes (Greiner, Germany) in serum-free Hams F14
medium supplemented with 0.25 % Albumax I (Life
Technologies, Paisley, UK) [39]. NGF (Calbiochem, UK),
GDF5 (Biopharm, Germany) and the broad_spectrum
caspase inhibitor Boc_D_FMK (Calbiochem, UK) were
added as indicated.
Neuronal survival was estimated by counting the num-
ber of attached neurons within a 12 × 12 mm grid in the
centre of each dish 2 h after plating and again after 24 h,
and expressing the 24-h count as a percentage of the 2-h
count [39]. Analysis of the size and complexity of neurite
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arbors was carried out 24 h after plating. The neurite ar-
bors were labeled by incubating the neurons with the
fluorescent vital dye calcein-AM (1:1000, Invitrogen,
Paisley, UK). Images of neurite arbors were acquired by
fluorescence microscopy and analyzed to obtain total
neurite length, number of branch points and Sholl pro-
files [40].
For compartment cultures, the neurons were seeded in
one compartment of a two compartment microfluidic
device (Xona Microfludics, CA, USA) and the medium
in both compartments was supplemented with 10 ng/ml
NGF to promote the growth of axons in both compart-
ments. 10 ng/ml GDF5 was added either to the axon
compartment or the soma compartment at plating, and
axon growth was assessed 24 h later following addition
of the fluorescent vital dye Calcein-AM (Invitrogen) to
the axonal compartment to label axons in this compart-
ment. ImageJ was used to measure the lengths of the 10
longest axons per random field (distances to the 10 fur-
thest growth cones from the compartment barrier) to
obtain a mean measurement for each field. Means of
these measurements were obtained from 7 separate ran-
dom fields along the microfluidic barrier of each com-
partment culture.
For the retrograde signaling experiments, the neurons
were incubated with 10 ng/ml NGF in both compart-
ments for 12 h before 10 ng/ml GDF5 was added to the
axon compartment, followed by addition of calcein-AM
to identify which neurons had projected axons into the
axonal compartment. Cultures where immediately fixed
and stained for phospho-Smad, as described below.
Neuron transfection and reporter assays
SCG neurons were transfected as previously described
[41] with the GFP-based Cignal Smad Reporter (SABios-
ciences, UK) and either an empty control plasmid or the
caBMPR-IB plasmid together with either a Smad decoy
(double stranded DNA oligonucleotide, 5′-gtacattgtc
agtctagacataact-3′) prepared as described previously or
a scrambled control decoy oligonucleotide (double
stranded DNA oligonucleotide, 5′-atcataatttggaactgtagt
ccg-3′). Reporter activity is expressed as the mean
fluorescence intensity of individual cells as previously
described [41].
Immunocytochemistry
Cultures were fixed in 4 % paraformaldehyde at room
temperature for 10 min, washed with phosphate buffered
saline (PBS) and blocked with 5 % bovine serum albumen
(BSA) and 0.1 % TritronX-100 in PBS for 1 h at room
temperature. The cells were incubated overnight with pri-
mary antibody in 1 % BSA at 4 °C. The following primary
antibodies were used: rabbit polyclonal anti-BMPR1A
(Abcam, Cambridge, UK, 1/200, catalogue number
ab38560), rabbit polyclonal anti-BMPR1B (Abcam, Cam-
bridge, UK, 1/200, catalogue number ab175385), rabbit
polyclonal anti-BMPR2 (Abcam, Cambridge, UK, 1/200,
catalogue number ab124463), rabbit polyclonal anti-
ACVR2A (Abcam, Cambridge, UK, 1/200, catalogue num-
ber ab96793), rabbit polyclonal anti-phospho-Smad1/5
(Ser463/465) (41D10) (Cell Signaling, Danvers, MA, USA,
1:100, catalogue number 9516) and β-III tubulin (Abcam,
Cambridge, UK, 1:500, ab41489). After washing, the cul-
tures were incubated with an Alexa-Fluor-labeled second-
ary antibody (1:500 Alexa Fluor 488 anti-rabbit, Life
Technologies, UK, catalogue number A-1108 and 1:500
Alexa Fluor 594 anti-chicken, Abcam, Cambrdige, UK,
catalogue number ab150172) for 1 h and counterstained
with DAPI (Chemicon) where indicated. Quantification of
nuclear staining of phospho-Smad1/5/8 was carried out as
described [42].
Immunohistochemistry
The iris and submandibular salivary gland of wild type
and mice that are heterozygous or homozygous for the
GDF-5bp mutation were fixed in 4 % paraformaldehyde
and 0.1 % TritonX-100 for 24 h and were cryoprotected
in 30 % sucrose before freezing. 15 μm serial sections
were blocked with 5 % BSA containing 0.1 % TritonX-
100 in PBS for 1 h at room temperature, and then incu-
bated for 18 h at 4 °C with a rabbit anti-tyrosine hydrox-
ylase polyclonal antibody (Merck-Millipore, Dundee,
UK, catalogue number AB152) diluted 1:200 in PBS with
1 % BSA together with or without anti-GDF5 (R&D sys-
tems, 1:50 or Biopharm GmBh, 1:100). The sections
were washed and incubated with appropriate secondary
antibodies (Alexa-Fluor, Invitrogen, 1:500). The density
of tyrosine hydroxylase-positive sympathetic fibers was
determined as described [26]. All imaging and quantifi-
cation was carried out blind.
Whole-Mount preparations
Paraformaldehyde fixed tissue was processed to label
tyrosine hydroxylase-positive sympathetic fibers by
DAB-HRP staining followed by clearing in benzyl alco-
hol:benzyl benzoate as described previously [26]. To
compare the extent of sympathetic nerve branching, a
modified line-intercept method was used. Using ImageJ,
a grid of 24 squares (4 × 6 squares, 158 μm side length
per square) was aligned in a standard orientation on im-
ages of the trachea using the lateral axonal bundle enter-
ing the trachea as a guide. The number of fibre bundles
intersecting the sides of squares in the grid was scored
blind. Fibre density was estimated using the formula
πDI/2, where D is the interline interval and I the mean
number of intersections along one side of each square in
the grid.
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Quantification of neuron number in the SCG
Estimates of the numbers of neurons in the SCG of wild
type and Gdf5bp mice were carried out by stereological
analysis of 8 μm serial sections of the ganglia as de-
scribed [25].
Western blotting
This was carried out as described [43]. Extracted proteins
were transferred to PVDF membranes which were blocked
with 5 % dried milk in PBS with 0.1 % Tween-20 and were
incubated overnight with anti-phospho-Smad1/5/8 (1:1000;
Cell Signaling), anti-β-III tubulin (1:10000; Promega) or
anti-ERK1/2 (1:1000; Cell Signaling). The appropriate
peroxidase-linked secondary antibody (1:2000; Promega)
was used to detect each primary antibody on the blots and
staining was visualized using ECL plus (Amersham).
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